# Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

> **NCT00006364** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 50 (actual)

## Conditions studied

- Childhood Chronic Myelogenous Leukemia
- Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Chronic Phase Chronic Myelogenous Leukemia
- Relapsing Chronic Myelogenous Leukemia

## Interventions

- **DRUG:** omacetaxine mepesuccinate
- **OTHER:** pharmacological study
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00006364
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-11
- **Primary completion:** 2005-09
- **Final completion:** —
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2013-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006364, "Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00006364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*